Compare LICN & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LICN | PLUR |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 18.5M |
| IPO Year | 2021 | 2001 |
| Metric | LICN | PLUR |
|---|---|---|
| Price | $1.11 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 17.1K | ★ 24.5K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,016,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $1.06 |
| 52 Week High | $9.49 | $4.87 |
| Indicator | LICN | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 32.26 |
| Support Level | $1.03 | N/A |
| Resistance Level | $1.40 | $1.85 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 59.52 | 10.80 |
Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational, and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and the sales of financial and taxation training software.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.